Fulgide A/S, a biotech company specializing in precision cancer surgery, has selected a laser system to advance the development of photothermal therapy (PTT) alongside its lead product, FG001. FG001, designed to bind urokinase-type plasminogen activator receptor (uPAR), fluoresces and targets various solid cancer types, including aggressive brain cancer, head and neck cancer, and lung cancer.
FG001 not only aids surgeons in visually identifying cancer cells during surgery but also possesses photothermal therapy properties. This allows for the selective destruction of cancer cells using near-infrared light, promising significant improvements in cancer treatment outcomes.
The chosen laser system provides the necessary light to activate FG001 and offers robust support for clinical development and commercialization efforts. Its adaptability allows for diverse applications, including treating local cancer recurrence and addressing inoperable cancers.
Morten Albrechtsen, CEO of FluoGuide, emphasizes the potential of this development: “We have now selected the laser system to support the further development of FG001 as photothermal cancer therapy. An application with considerable potential for improving cancer treatment and outcomes for patients.”
As FluoGuide advances through the phase III program for fluorescence-guided surgery in aggressive brain cancer, they are also exploring integrating PTT into their approach. With over 90% of aggressive brain cancer patients experiencing local recurrence, there is a critical need to enhance surgical outcomes. Clinical data affirm the safety and efficacy of FG001, highlighting its ability to improve tumor removal precision while preserving healthy tissue.
FluoGuide aims to revolutionize cancer surgery by reducing recurrence rates and surgical complications while improving treatment outcomes, potentially reducing healthcare costs in the process.